EBSCO Clinical Decisionstoday announced DynaMed®, a leading clinical decision support solution from EBSCO Information Services (EBSCO), now publishes summaries of select articles from the New England ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 ...
Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New ...
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...
US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...
Israeli pharma and generics player Teva (NYSE: TEVA), says the New England Journal of Medicine has published Phase III data from the SPACE trial showing Ajovy (fremanezumab-vfrm) reduced monthly ...
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- In the Largest Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results